Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 100,000 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 100,000 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00. Following the sale, the chief executive officer owned 660,482 shares of the company’s stock, valued at approximately $58,895,179.94. This trade represents a 13.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, October 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $60.99, for a total value of $1,829,700.00.
• On Tuesday, September 16th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded up $27.68 during trading on Monday, hitting $94.30. The company’s stock had a trading volume of 7,492,731 shares, compared to its average volume of 772,142. The firm has a market cap of $6.78 billion, a price-to-earnings ratio of -26.27 and a beta of 2.28. The company has a 50-day moving average of $61.48 and a 200-day moving average of $50.05. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The business had revenue of $2.76 million for the quarter, compared to analysts’ expectations of $23.15 million. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Institutional Trading of Kymera Therapeutics

Several institutional investors have recently made changes to their positions in KYMR. US Bancorp DE raised its stake in Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Kymera Therapeutics by 9.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock valued at $156,000 after buying an additional 248 shares in the last quarter. Larson Financial Group LLC raised its position in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Kymera Therapeutics by 642.9% during the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after buying an additional 540 shares during the last quarter. Finally, Comerica Bank lifted its holdings in shares of Kymera Therapeutics by 3.6% in the first quarter. Comerica Bank now owns 21,374 shares of the company’s stock worth $585,000 after buying an additional 743 shares in the last quarter.

Analyst Ratings Changes

KYMR has been the topic of a number of recent research reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $73.00 target price on shares of Kymera Therapeutics in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Wednesday, October 8th. Truist Financial raised their price objective on Kymera Therapeutics from $68.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, November 26th. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Wells Fargo & Company increased their target price on shares of Kymera Therapeutics from $53.00 to $69.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics has an average rating of “Buy” and a consensus price target of $81.68.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.